Due to this prevalence of STAT5 mutations and their negative prognostic indications, inhibition of STAT molecules may be an appealing therapeutic approach in PTCL. This evidence concerns the gene SOAT1 and mature T-cell and NK-cell non-Hodgkin lymphoma.